Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Biodegradable and Eco-friendly Smart Hydrogels for the Sustained Intraperitoneal Release of Chemotherapeutics as a Novel Local Therapy Approach for Advanced Ovarian Cancer

Obiettivo

Ovarian Cancer (OC) is usually diagnosed in advanced stages when metastasis into the intra-abdominal (i.a.) cavity already occurred. The OC standard-of-care efficacy is hampered by drugs high systemic toxicity and the early appearance of resistance. Thus, advanced OC remains an unmet clinical need, forcing the need for alternative therapies based on drugs local slow-release at the i.a. cavity. Hydrogels (HG) have been proposed as in situ drug sustained release systems in the biomedical field. Their application avoids off-target effects caused by drugs systemic administration and improves their therapeutic efficacy. Thermo-responsive HG (TR-HG) gained special attention due to their ability to be liquid at room temperature, enabling their injection, and jellify at body temperature. Accordingly, the goal of HydroTheC is to provide a new on-demand TR-HG as a new delivery depot system for the impairment of OC i.a. spread. The innovative character of the proposed HG relies on: i) Use of Natural and eco-friendly components and synthesis methods recognized by Green Chemistry rules, ii) Use of in silico bioinformatic tools to reduce unnecessary expenses and environmental impact, iii) Nanoparticles incorporation to create e multicompartment HG system, and iv) On-demand character, due to its easy adaptability to any drug or clinical conditions that would benefit from local therapy. For the project success will be crucial the team interdisciplinary character, as well as the perfect match of knowledge existent between the candidate and associated institutions. In the end, it is expected to obtain a novel HG that will significantly increase the standard-of-care therapeutic window, increasing OC patients survival and quality-of-life. Moreover, the designed HG would serve as a technological platform adaptable to different clinical applications, paving the way toward more personalized therapies, and bringing new alternatives to clinical situations with limited therapeutic options.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2022-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
Contributo netto dell'UE
€ 221 390,88
Indirizzo
PASSEIG VALL D HEBRON 119-129 EDIFICIO CENTRAL
08035 BARCELONA
Spagna
Regione
Este Cataluña Barcelona
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato

Partner (2)